China Insulin Drugs And Delivery Devices Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 6.20 Billion |
| Market Size (2029) | USD 8.90 Billion |
| CAGR (2024 - 2029) | 2.60 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
China Insulin Drugs And Delivery Devices Market Analysis
The China Insulin Drugs And Delivery Devices Market size is estimated at USD 6.20 billion in 2024, and is expected to reach USD 8.90 billion by 2029, growing at a CAGR of 2.60% during the forecast period (2024-2029).
For a person with type 1 diabetes, insulin therapy is vital for replacing the insulin which the body doesn't produce. People with type 2 diabetes or gestational diabetes need insulin therapy if other treatments, such as diabetes medications and other lifestyle changes, are not able to keep blood glucose levels within the desired range. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people.
Insulin is a prescription drug in China and requires a prescription. Hospitals are the main places where patients can obtain insulin products. Patients can get medicines directly from the hospital pharmacy without a referral. Despite the implementation of national health insurance and its universal coverage, a large proportion of outpatient drugs is still required to pay. To reduce the burden on patients, China began implementing a National Essential Medicine System, which aims to guarantee the use of drugs by patients.
The rising diabetes prevalence and the aforementioned factors are expected to boost the insulin market's growth.
China Insulin Drugs And Delivery Devices Market Trends
Rising diabetes prevalence
In China, Diabetes Population is expected to increase with a CAGR greater than 1.05% over the forecast period.
According to IDF Diabetes Atlas 2021, an estimated 141 million adults were living with diabetes in China, which is a rise of 20% over the past two years. It has the highest number of deaths from diabetes in the Western Pacific region, at approximately 1.4 million, and the second-highest diabetes-related health expenditure in the world. More than half of adults currently living with diabetes in China are undiagnosed.
China has the world's largest population of people with diabetes, which continues to grow with the country's rapid urbanization. Chinese Ministry of Health has established a network of National Demonstration Areas to develop pilot projects for health promotion, detection, and control of chronic diseases. Various local government departments with country officials are responsible for overall coordination. Primary care providers promote education and self-management of health conditions through appropriate dietary changes, control of tobacco use, and physical activity, which are beneficial for diabetes control.
As a long-term strategy, China is extending efforts at health promotion, detection, and control of diabetes with academic medical centers (AMCs) and hospitals with effective primary care. AMCs are usually overcrowded with patients with simple conditions, while the primary care system is under-equipped with basic medical infrastructure and an under-qualified workforce. The State Council has encouraged health system integration by promoting a hierarchical medical system, a policy that attempts to attract more patients to primary health centers before going to AMCs.
Therefore, owing to the increasing diabetes prevalence, the studied market is anticipated to witness growth over the analysis period.
The Insulin Pumps Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period
Insulin Pump is expected to grow with a CAGR of more than 5.8% in the market over the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration.
An insulin pump is a small battery-operated electronic device that delivers insulin continuously or whenever required automatically. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. The pump is programmed to deliver insulin into the body through thin plastic tubing known as the infusion set. The pump is worn outside the body, while the infusion set has a fine needle or flexible cannula that is inserted just below the skin, where it stays in place for two to three days.
The pump mimics the human pancreas. Whenever food is eaten, the pump is programmed to deliver a surge of insulin into the body the way the pancreas does in people without diabetes. Between meals, a small and steady rate of insulin is delivered. Insulin pump therapy is a well-established insulin administration method for type 1 diabetes people. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.
The use of continuous subcutaneous insulin infusion or insulin pumps and continuous glucose monitoring systems have improved the care and quality of life for patients and are widely used in the ambulatory setting. Increasingly, this technology is also being used in the hospital setting. The Healthy China 2030 Plan, approved by the State Council and the Party's Central Committee, puts diabetes, along with cancer, hypertension, and cardiovascular diseases, in the four major non-communicable diseases with a goal to 'control the prevalence and reduce the probability of early death.' The central government launched a 2017-2025 plan to control non-communicable diseases, which includes increasing the regular monitoring and self-management rate for diabetes patients from 50% to 70% by 2025. Such factors are expected to boost market growth.
China Insulin Drugs And Delivery Devices Industry Overview
The China Insulin Drugs and Delivery Devices Market is moderately consolidated, with few significant and generic players. The major players are working on innovations which is evident from the companies spending on research and developments to strengthen their market presence.
China Insulin Drugs And Delivery Devices Market Leaders
-
Gan & Lee Pharmaceuticals
-
Medtronic
-
Eli Lilly and Company
-
Sanofi
-
Novo Nordisk
*Disclaimer: Major Players sorted in no particular order
China Insulin Drugs And Delivery Devices Market News
- October 2022: Novo Nordisk announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300).
- July 2022: Gan & Lee Pharmaceuticals Co., Ltd. announced that China's National Medical Products Administration (NMPA) cleared its investigational new drug application for GZR4 to improve the management of diabetes. GZR4, a new generation of once-weekly ultra-long-acting insulin, is expected to be dosed once a week by subcutaneous injection in humans to achieve smooth control of basal blood glucose for one week.
China Insulin Drugs And Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Drugs
5.1.1 Basal or Long-acting Insulins
5.1.1.1 Lantus (Insulin Glargine)
5.1.1.2 Levemir (Insulin Detemir)
5.1.1.3 Toujeo (Insulin Glargine)
5.1.1.4 Tresiba (Insulin Degludec)
5.1.1.5 Basaglar (Insulin Glargine)
5.1.2 Bolus or Fast-acting Insulins
5.1.2.1 NovoRapid/Novolog (Insulin aspart)
5.1.2.2 Humalog (Insulin lispro)
5.1.2.3 Apidra (Insulin glulisine)
5.1.2.4 FIASP (Insulin aspart)
5.1.2.5 Admelog (Insulin lispro Sanofi)
5.1.3 Traditional Human Insulins
5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard
5.1.3.2 Humulin
5.1.3.3 Insuman
5.1.4 Combination Insulins
5.1.4.1 NovoMix (Biphasic Insulin aspart)
5.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)
5.1.4.3 Xultophy (Insulin degludec and Liraglutide)
5.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)
5.1.5 Biosimilar Insulins
5.1.5.1 Insulin Glargine Biosimilars
5.1.5.2 Human Insulin Biosimilars
5.2 Devices
5.2.1 Insulin Pumps
5.2.1.1 Insulin Pump Devices
5.2.1.2 Insulin Pump Reservoirs
5.2.1.3 Insulin Infusion sets
5.2.2 Insulin Pens
5.2.2.1 Cartridges in reusable pens
5.2.2.2 Disposable insulin pens
5.2.3 Insulin Syringes
5.2.4 Insulin Jet Injectors
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 Biocon
7.1.5 Julphar
7.1.6 Medtronic
7.1.7 Ypsomed
7.1.8 Becton Dickinson
7.1.9 Gan and Lee
- *List Not Exhaustive
7.2 COMPANY SHARE ANALYSIS
7.2.1 Insulin Drugs
7.2.1.1 Novo Nordisk
7.2.1.2 Sanofi
7.2.1.3 Eli Lilly
7.2.1.4 Others
7.2.2 Insulin Delivery Devices
7.2.2.1 Medtronic
7.2.2.2 Ypsomed
7.2.2.3 Becton Dickinson
7.2.2.4 Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
China Insulin Drugs And Delivery Devices Industry Segmentation
Insulin delivery devices are used to deliver insulin based on a patient's insulin regimen, ability to manipulate or operate a particular device, insurance coverage, or ability to afford a particular device and daily schedule. The China Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins) and Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.
| Drugs | |||||||
| |||||||
| |||||||
| |||||||
| |||||||
|
| Devices | |||||
| |||||
| |||||
| Insulin Syringes | |||||
| Insulin Jet Injectors |
China Insulin Drugs And Delivery Devices Market Research Faqs
How big is the China Insulin Drugs And Delivery Devices Market?
The China Insulin Drugs And Delivery Devices Market size is expected to reach USD 6.20 billion in 2024 and grow at a CAGR of 2.60% to reach USD 8.90 billion by 2029.
What is the current China Insulin Drugs And Delivery Devices Market size?
In 2024, the China Insulin Drugs And Delivery Devices Market size is expected to reach USD 6.20 billion.
Who are the key players in China Insulin Drugs And Delivery Devices Market?
Gan & Lee Pharmaceuticals, Medtronic, Eli Lilly and Company, Sanofi and Novo Nordisk are the major companies operating in the China Insulin Drugs And Delivery Devices Market.
What years does this China Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?
In 2023, the China Insulin Drugs And Delivery Devices Market size was estimated at USD 6.04 billion. The report covers the China Insulin Drugs And Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the China Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
China Insulin Drugs And Delivery Devices Industry Report
Statistics for the 2024 China Insulin Drugs And Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. China Insulin Drugs And Delivery Devices analysis includes a market forecast outlook to for 2024 to 2029) and historical overview. Get a sample of this industry analysis as a free report PDF download.
